{
    "nct_id": "NCT06015022",
    "official_title": "Phase II Randomized Controlled Trial of Epigallocatechin Gallate for Hepatocellular Carcinoma Chemoprevention",
    "inclusion_criteria": "* Adults (≥ 18 years-old)\n* Clinically and/or histologically diagnosed cirrhosis\n* No active hepatic decompensation\n* No prior history of HCC\n* Adequate hematologic, hepatic, and renal function\n* Karnofsky performance status score ≥70\n* Both sexes and all racial/ethnic groups will be considered\n* FIB-4 index > 3.25\n* High-risk PLSec at baseline\n* Absence of HLA-B*35:01\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior or ongoing use of EGCG\n* History of adverse reaction to green tea products\n* Severe obesity (BMI > 40 kg/m2)\n* Active drinking\n* EGCG treatment <4 weeks or <80% of planned regimen at the end of week 4\n* HCC development during the study",
    "miscellaneous_criteria": ""
}